<italic>NTRK3</italic>-Rearranged Prostatic Acinar Adenocarcinoma: Report of a Patient and Review of the Literature.

Molecular investigations have led to increased therapeutic options for prostatic adenocarcinoma. A single case report of a <italic>PRPSAP1</italic>::<italic>NTRK3</italic> gene fusion occurring in prostate cancer was previously reported. A review of the literature revealed that <italic>NTRK</italic> gene rearrangements are exceedingly rare molecular events in prostate cancer. <italic>NTRK</italic> gene fusions can be oncogenic drivers or develop as resistance mechanisms. The tumor-agnostic approvals of TRK inhibitors by the FDA provide additional rationale for molecular investigations of aggressive prostatic adenocarcinomas. This may prove to be an additional therapeutic option for patients with aggressive prostatic carcinomas refractory to initial therapy. We report a case of an aggressive castrate-resistant prostatic adenocarcinoma with a <italic>BMP6</italic>::<italic>NTRK3</italic> gene fusion. [ABSTRACT FROM AUTHOR]